Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Healthcare Biotechnology
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch... see more

TSX:SVA - Post Discussion

Sernova Corp > Total Compensation Indecent
View:
Post by Sailboatdream on Apr 05, 2023 8:03pm

Total Compensation Indecent

This taken from the management circular on sedar.  No wonder they want to create more common shares!  Total comp invludes a hefty portion of shares and options.

Frank Holler - Executive Chair
2022:    $912,750
2021:    $66,188
2022:    $37,792

Philip Toleikis - President & CEO
2022:    $5,577,868
2021:    $634,000
2020:    $367,000

David Swetlow - CFO
2022:    $3,285,144
2021:    $344,838
2020:    $183,750

Frank Shannon - VP Clinical & Regulatory
2022:    $636,300
2021:    $60,737 (likely partial year)
2020:    NA

Chris Barnes - VP Investor Relations
2022:    $339,401
2021:    NA
2020:    NA
Be the first to comment on this post
Sernova Corp